FI3920891T3 - Nopeasti hajoavat kannabinoiditabletit - Google Patents

Nopeasti hajoavat kannabinoiditabletit Download PDF

Info

Publication number
FI3920891T3
FI3920891T3 FIEP20727578.5T FI20727578T FI3920891T3 FI 3920891 T3 FI3920891 T3 FI 3920891T3 FI 20727578 T FI20727578 T FI 20727578T FI 3920891 T3 FI3920891 T3 FI 3920891T3
Authority
FI
Finland
Prior art keywords
tablet
tablet according
cannabinoids
sugar alcohol
combinations
Prior art date
Application number
FIEP20727578.5T
Other languages
English (en)
Finnish (fi)
Inventor
Heidi Ziegler Bruun
Dorte Schackinger Boesen
Bruno Provstgaard Nielsen
Original Assignee
Nordiccan As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA3040513A external-priority patent/CA3040513C/en
Priority claimed from CA3040547A external-priority patent/CA3040547C/en
Priority claimed from CA3040532A external-priority patent/CA3040532C/en
Priority claimed from US16/386,477 external-priority patent/US10925853B2/en
Priority claimed from CA3065042A external-priority patent/CA3065042C/en
Priority claimed from US16/713,580 external-priority patent/US11633351B2/en
Application filed by Nordiccan As filed Critical Nordiccan As
Application granted granted Critical
Publication of FI3920891T3 publication Critical patent/FI3920891T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
FIEP20727578.5T 2019-04-17 2020-04-17 Nopeasti hajoavat kannabinoiditabletit FI3920891T3 (fi)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CA3040513A CA3040513C (en) 2019-04-17 2019-04-17 An oral cannabinoid tablet
CA3040547A CA3040547C (en) 2019-04-17 2019-04-17 Cannabinoid lozenge formulation
CA3040532A CA3040532C (en) 2019-04-17 2019-04-17 Lozenge for improved delivery of cannabinoids
US16/386,477 US10925853B2 (en) 2019-04-17 2019-04-17 Oral cannabinoid tablet
CA3065042A CA3065042C (en) 2019-12-13 2019-12-13 Fast disintegrating cannabinoid tablets
US16/713,580 US11633351B2 (en) 2019-12-13 2019-12-13 Fast disintegrating cannabinoid tablets
PCT/DK2020/050102 WO2020211915A1 (en) 2019-04-17 2020-04-17 Fast disintegrating cannabinoid tablets

Publications (1)

Publication Number Publication Date
FI3920891T3 true FI3920891T3 (fi) 2024-03-19

Family

ID=70802555

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20727578.5T FI3920891T3 (fi) 2019-04-17 2020-04-17 Nopeasti hajoavat kannabinoiditabletit

Country Status (12)

Country Link
EP (2) EP4268815A3 (cg-RX-API-DMAC10.html)
JP (1) JP7556882B2 (cg-RX-API-DMAC10.html)
CN (1) CN113784704A (cg-RX-API-DMAC10.html)
AU (1) AU2020258631B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021020523A2 (cg-RX-API-DMAC10.html)
DK (1) DK3920891T3 (cg-RX-API-DMAC10.html)
ES (1) ES2975266T3 (cg-RX-API-DMAC10.html)
FI (1) FI3920891T3 (cg-RX-API-DMAC10.html)
MX (1) MX2021012712A (cg-RX-API-DMAC10.html)
PL (1) PL3920891T3 (cg-RX-API-DMAC10.html)
WO (1) WO2020211915A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202107389B (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020412501A1 (en) * 2019-12-24 2022-08-18 Cannadol Pharmaceuticals Ltd Compositions comprising terpenes and their use in the treatment or alleviation of pain or anxiety
TWI923583B (zh) * 2020-04-14 2026-05-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽之用於經口投予之醫藥組成物
LT4243797T (lt) * 2020-11-16 2026-06-10 Orcosa Inc. Greitos infuzijos platforma ir kompozicijos, skirtos žmonių terapiniam gydymui
US11672761B2 (en) * 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
CN114748429A (zh) * 2020-12-29 2022-07-15 汉义生物科技(北京)有限公司 一种水溶性大麻素制剂及其制备方法
JP2023010677A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
JP2023010676A (ja) * 2021-07-09 2023-01-20 株式会社東洋新薬 固形組成物
US20240415853A1 (en) * 2023-03-21 2024-12-19 Fertin Pharma A/S Cannabinoid Self-Emulsifying Systems
JP2025529608A (ja) * 2023-07-24 2025-09-09 ポビバ コーポレーション てんかんを処置する為の組成物及び方法
DK202330231A1 (en) * 2023-09-27 2025-04-10 Fertin Pharma As Cannabidiol for alleviating xerostomia
CN118021744A (zh) * 2024-02-05 2024-05-14 谛邈生物科技(北京)有限公司 一种大麻二酚型大麻素化合物冻干闪释片及其制备方法
DK202430722A1 (en) * 2024-11-25 2026-06-09 Fertin Pharma As Sugar free soft chew tablets

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
CA2664315C (en) * 2006-09-15 2016-01-19 Echo Pharmaceuticals B.V. Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances
EP2164462B1 (de) * 2007-06-06 2017-05-31 Basf Se Pharmazeutische formulierung für die herstellung von schnell zerfallenden tabletten
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
US9023322B2 (en) * 2008-03-26 2015-05-05 Stichting Sanammad Chewing gum compositions comprising cannabinoids
WO2009151072A1 (ja) * 2008-06-13 2009-12-17 大日本住友製薬株式会社 口腔内速崩壊錠及びその製造方法
KR20130076015A (ko) * 2011-12-28 2013-07-08 주식회사 삼양바이오팜 높은 경도를 갖는 속붕정 및 이의 제조 방법
EP2609912A1 (en) * 2011-12-30 2013-07-03 Deva Holding Anonim Sirketi Pharmaceutical combination of fingolimod and nabiximols
CA2845443A1 (en) * 2014-03-04 2015-09-04 Pharmascience Inc. Orally disintegrating tablet of nabilone and method of manufacturing
CA2992923C (en) * 2014-07-21 2021-06-29 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal and sublingual administration of cannabinoids
WO2016092539A1 (en) * 2014-12-07 2016-06-16 One World Cannabis Ltd Use of cannabis to treat migraine
EP3253368A4 (en) * 2015-02-02 2018-08-22 Axim Biotechnologies, Inc. Cannabinoid and sugar alcohol complex, methods to make and use
US10765658B2 (en) * 2016-06-22 2020-09-08 Mastix LLC Oral compositions delivering therapeutically effective amounts of cannabinoids
KR20220132674A (ko) * 2016-08-03 2022-09-30 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
CA3052564A1 (en) * 2017-02-05 2018-08-09 CannTab Therapeutics Limited Flash-melt cannabinoid formulations
US10772837B2 (en) * 2017-03-16 2020-09-15 CannTab Therapeutics, Ltd Modified release multi-layer tablet cannabinoid formulations
JP2020520966A (ja) * 2017-05-22 2020-07-16 ジービーエス グローバル バイオファーマ,インコーポレイテッド Trpv1を標的にするミルセン及びカンナビノイド含有組成物
JP2021513566A (ja) * 2018-02-09 2021-05-27 ニュートリスキ インターナショナル インク.Neutrisci International Inc. スチルベノイドとカンナビノイドとの共結晶を含む組成物

Also Published As

Publication number Publication date
MX2021012712A (es) 2021-11-12
BR112021020523A2 (pt) 2021-12-07
JP7556882B2 (ja) 2024-09-26
EP4268815A3 (en) 2024-02-21
EP3920891B1 (en) 2024-02-21
ZA202107389B (en) 2025-04-30
CN113784704A (zh) 2021-12-10
PL3920891T3 (pl) 2024-05-20
ES2975266T3 (es) 2024-07-04
EP4268815A2 (en) 2023-11-01
AU2020258631B2 (en) 2023-11-02
AU2020258631A1 (en) 2021-10-28
DK3920891T3 (da) 2024-03-18
JP2022529037A (ja) 2022-06-16
WO2020211915A1 (en) 2020-10-22
EP3920891A1 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
JP2022529037A5 (cg-RX-API-DMAC10.html)
Ko et al. Flavonoids as therapeutic candidates for emotional disorders such as anxiety and depression: Y.-H. Ko et al.
CA2703698C (en) Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
Matsui et al. α-Glucosidase inhibitory profile of catechins and theaflavins
Zaklos-Szyda et al. Antidiabetic effect of polyphenolic extracts from selected edible plants as α-amylase, α-glucosidase and PTP1B inhibitors, and β pancreatic cells cytoprotective agents-a comparative study
CA2636634C (en) Cannabinoid-containing plant extracts as neuroprotective agents
US20180235917A1 (en) Compositions, methods and kits for treatment of diabetes and/or hyperlipidemia
AU2017341707A1 (en) An oral composition of extracted cannabinoids and methods of use thereof
Wang Natural plant resource flavonoids as potential therapeutic drugs for pulmonary fibrosis
WO2020018845A1 (en) Rapidly dissolving pharmaceutical compositions and method of manufacturing
Liu et al. Cytotoxic and antioxidant effects of the water extract of the traditional Chinese herb gusuibu (Drynaria fortunei) on rat osteoblasts
AU2020258631A1 (en) Fast disintegrating cannabinoid tablets
US20040071685A1 (en) Compositions and methods for increasing the bioavailability of plant polyphenols
EP3955897A1 (en) Cannabinoid lozenge formulation
US6524630B2 (en) Use of cocoa procyanidins combined with acelylsalicyclic acid as an anti-platelet therapy
Goswami et al. Flavonoids, isoflavonoids and others bioactives for insulin sensitizations
Makowczynska et al. Antioxidant activity of tissue culture-raised Ballota nigra L. plants grown ex vitro
Prada et al. Development, pharmacological and toxicological evaluation of a new tablet formulation based on Cassia grandis fruit extract
AU2001261004A1 (en) The use of cocoa procyanidins combined with acetylsalicyclic acid as an anti-platelet therapy
US12220397B2 (en) Brain health formulation
JP2010043035A (ja) サラシア属植物を含有する経口用組成物
Sa-Ngiamsuntorn et al. Hepatoprotective effects of Acanthopanax trifoliatus standardized leaf extract and its formulations in a HepG2 model
Fang et al. β‐Secretase (BACE1) inhibitors from natural products
ES3064715T3 (en) Powdered composition of mint oil extract and amaranth seeds flour
Nawangsari et al. Piper betel L. Leaf Extract Lozenges for Preventing Dental Caries for Children